A: ZINC FINGER NUCLEASE (ZFN) TECHNOLOGIES are leading the field into in vivo human studies, and we expect other technologies will eventually catch up. Innovation in delivery technology will enable the genome editing field to advance into new tissue types such as the brain and will make dosing titration possible. Additionally, we believe in the near future there will be a new chapter in medicine with genome editing therapies providing permanent cures for many of today’s most intractable and grievous illnesses.
SANDY MACRAE, M.B., CH.B., PH.D.
Sandy is president and CEO of Sangamo Therapeutics. He has over 20 years of leadership experience in the pharmaceutical industry encompassing various areas of clinical R&D and business development.